AD Drugs Market Predicted to Grow From $10.5 Billion to $24.5 Billion

A new market research report predicts that the global atopic dermatitis (AD) drugs market will grow at a compound annual growth rate of 9.1% from now through 2033, going from $10.5 billion in 2023 to $24.5 billion by 2033.

The report, from market.us, is titled, “Atopic Dermatitis Drugs Market Analysis By Drug Class (Biologics, PDE-4 Inhibitor, Corticosteroids, Calcineurin Inhibitors, and Other Drug Classes), By Route of Administration (Injectable, Topical, Oral), By End-User (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032.”

Factors cited as contributing to the market growth include the increasing significance of AD, the emergence of biologics, untapped opportunities, a strong pipeline, f avorable reimbursement policies in developing countries, various initiatives taken by the government, increasing awareness about the availability of treatments for the disease, rapid technological advancement, and increase in funding with the government support for R&D.

“North America dominates the market with a 52% revenue share,” the report stated, “driven by favorable reimbursement policies and the impact of the COVID-19 pandemic on hand atopic dermatitis cases.”